This paper is in the following e-collection/theme issue:

Pediatrics (147) Theme Issue: Digital Approaches for Pediatric Healthcare Delivery During the Coronavirus (Covid-19) Pandemic (37) Infectious Diseases (non-STD/STI) (1661) Epidemiologic Studies and Surveys in Child Health (28)

Published on in Vol 8 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/67546, first published .
Hospitalization and Mortality in Brazilian Children and Adolescents Due to COVID-19: Retrospective Study

Hospitalization and Mortality in Brazilian Children and Adolescents Due to COVID-19: Retrospective Study

Hospitalization and Mortality in Brazilian Children and Adolescents Due to COVID-19: Retrospective Study

Authors of this article:

Ana Carolina Pereira de Godoy1 Author Orcid Image ;   Reinaldo Bulgarelli Bestetti2 Author Orcid Image
Article Authors Cited by Tweetations Metrics

    1Hospital da Criança e Materinade de Sao José do Rio Preto-Brazil, Rua Floriano Peixoto 2950, Sao José do Rio Preto, Brazil

    2Faculdade de Medicina de Sao José do Rio Preto-Brazi, University of Ribeirão Preto, Sao José do Rio Preto, Brazil

    *all authors contributed equally

    Corresponding Author:

    Ana Carolina Pereira de Godoy, MD


    Background: COVID-19 is currently one of the most important medical challenges as it affects the entire population, with children and adolescents being infected as easily as adults.

    Objective: The objective of this study was to evaluate the prevalence of mortality in children and adolescents aged <19 years, compared to that of adults.

    Methods: This retrospective, observational study analyzed the medical records of all patients diagnosed with COVID-19 by real-time reverse transcription–quantitative polymerase chain reaction who were hospitalized at Hospital de Base and the Infant and Maternal Hospital of São José do Rio Preto, São Paulo, Brazil. Out of a total of 8986 hospitalized patients who were COVID-19 positive, 383 (4.26%) were children and adolescents aged <19 years (group 1), and 8603 (95.74%) were adults (group 2).

    Results: Overall, mortality was significantly higher (P<.001) in group 2 (2185/8603, 25.4%) compared to group 1 (12/383, 3.1%). A total of 11 (92%) of the 12 patients in group 1 that died had associated diseases. The mortality rates by age group were as follows: infants aged <1 year, 1.6% (2/123); children aged 1-4 years, 4% (4/95); children aged 5-9 years, 2% (1/47); adolescents aged 10-14 years, 2% (1/40); and adolescents aged 15-19 years, 5% (4/78).

    Conclusions: Mortality from COVID-19 in children and adolescents was significantly lower than that in adults and was associated with other comorbidities.

    JMIR Pediatr Parent 2025;8:e67546

    doi:10.2196/67546

    Keywords

    COVID-19; children; mortality; Brazil; retrospective study; morbidity; hospitalization 


    COVID-19 is currently one of the most important medical challenges as it affects the entire population, with children and adolescents being infected as easily as adults; children and adolescents often remain asymptomatic or have mild complaints due to their immature immune systems [1]. Advanced age and comorbidities such as hypertension, diabetes, ischemic heart disease, vascular disease, renal failure, obesity, dyspnea, and dementia have been reported to be associated with a greater risk of death among older people infected with COVID-19. Some studies have described pathophysiological insights into COVID-19–induced coagulopathy, endothelium disease, and angiogenesis-associated defects [2-4]. Most children and adolescents with COVID-19 have mild symptoms; however, coagulopathies have been associated with multisystem inflammatory syndrome—a postinfectious complication—in young patients [2].

    A study in Sergipe, Brazil, describing COVID-19 cases and deaths in children and adolescents reported 37 deaths before September 20, 2020, corresponding to a rate of 4.87 deaths per 100,000 of the population aged <19 years. Most children and adolescents had comorbidities such as chronic neurological diseases (n=7, 19%) and prematurity (n=4, 11%). Furthermore, most children and adolescents who died (n=18, 49%) were not admitted to intensive care units. This was possibly related to the great regional inequalities in health care [5].

    A study in England reported that 4% (1408/35,200) of tests performed in children and adolescents aged <16 years were positive for SARS-CoV-2, compared to 19.1% to 34.9% in adults [3]. A review of pregnant women with COVID-19 reported that SARS-CoV-2 was detected in 4.3% (19/444) of newborns at birth. Elevated levels of immunoglobulin M and G serum antibodies were reported in one case, but the swab test was negative [4]. Mortality in children is higher in those with existing diseases compared to those without comorbidities [6].

    Regarding the prognosis, metabolic acidosis, hyperlactatemia, hyperglycemia, altered liver function parameters, and hypoproteinemia are biochemical markers associated with the severity of the disease in children infected with SARS-CoV-2. Anemia and ketoacidosis are important risk factors for death in the pediatric patient population who are infected [7]. Gastrointestinal involvement is common in children hospitalized for acute COVID-19 infection and multisystem inflammatory syndrome, but gastrointestinal involvement is not associated with critical illness, length of hospital stay, or mortality in acute cases of COVID-19 [8].

    In a study of pediatric COVID-19 epidemiology, Sousa et al [9] highlighted the presence of comorbidities in patients aged <2 years, in particular those related to congenital heart disease, Down syndrome, obesity, and asthma. Furthermore, these authors reported differences in morbidity and mortality due to regional disparities, with higher rates in regions with less resources, as is the case in the economically less favored northern and northeastern regions of Brazil. In their analysis of 2020 deaths of children that occurred throughout Brazil, 42% occurred in children aged <2 years and 43% occurred in adolescents aged 10‐19 years, with children aged 2‐10 years being relatively protected. A total of 58% of deceased patients had at least one comorbidity. It is noteworthy that 69% of deaths were observed in Black or multiracial patients, 25.5% in White patients, and 5% in Indigenous patients, with approximately 60% occurring in the northern and northeastern regions of Brazil.

    It is also worth remembering the prolonged symptoms that are associated with COVID-19—notably, fatigue, headaches, drowsiness, and difficulty concentrating—as well as the impact of social isolation, which can cause psychosocial disorders and learning gaps that can have a major impact on children’s education [10,11].

    An American study reports that pediatric patients with a recent relapse of cancer have a higher chance of all-cause mortality when infected with COVID-19 [12].

    The objectives of this study were to evaluate the mortality of children and adolescents and compare it with that of adults in a cohort of 8986 patients hospitalized for COVID-19 in a university hospital complex in Brazil.


    Patients and Setting

    A retrospective, observational study was performed to analyze the medical records of all patients diagnosed with COVID-19 who were hospitalized at Hospital de Base and the Infant and Maternal Hospital of São José do Rio Preto, São Paulo, Brazil, from March 2020 to July 2023.

    All patients diagnosed with COVID-19 by reverse transcription–quantitative polymerase chain reaction and admitted to these hospitals were included in this study. Patients hospitalized for other illnesses and those who tested negative for COVID-19 during this period were excluded.

    Patients aged <19 years were categorized as children or adolescents (group 1), and those aged ≥19 years were categorized as adults (group 2). Group 1 was further subdivided by age: <1 year, 1‐4 years, 5‐9 years, 10‐14 years, and 15‐19 years. The monthly occurrence of COVID-19 was evaluated, with mortality in children and adolescents being compared to that in adults. Existing diseases and the occurrence of other viral infections were identified over the same period in patients aged <19 years who were COVID-19 positive.

    Ethical Considerations

    The study was approved by the ethics committee of the Medical School in São José do Rio Preto under approval 6.086.468 (CAAE 67915723.3.0000.5415; date approved: May 29, 2023).

    For this study, the institution permitted the analysis of these records, guaranteeing the use of data only in this research protocol. Absolute confidentiality was maintained during the data collection and use thereof. Safeguards were taken to collect data from medical records in the institution’s own archives department; patient charts were not removed for any reason.

    The signed consent form was authorized by the ethics committee to be waived, because these were medical records and due to the impossibility of contacting family members and those who have died. Thus, the authors guaranteed the privacy and confidentiality of the data obtained, fully preserving the anonymity of the participants in accordance with the Declaration of Helsinki.

    Statistical Analysis

    Data were tabulated in Microsoft Excel spreadsheets, with statistical analysis conducted using StatsDirect 3 software (StatsDirect Ltd). Descriptive statistics, Fisher exact test, chi-square test, and odds ratio were used considering an α error of 5% (P≤.05).


    Between March 2020 and July 2023, a total of 8986 patients who were COVID-19 positive were hospitalized, 383 (4.26%) of whom were aged <19 years and 8986 (95.74%) were aged ≥19 years (mean age 57.66 y; Figure 1). Overall, 12 children and adolescents died, that is, 3.1% of the 383 patients in this age group. The number of deaths in group 2 (adults) was 2185, that is, equivalent to 25.4% of the 8603 hospitalized adults and 99.45% (2185/2197) of overall deaths. Mortality was significantly higher for adults than children and adolescents aged <19 years (Yates-corrected χ2 test=98.127501, P<.001; odds ratio 10.317, 95% CI 5.793‐18.374).

    ‎
    Figure 1. Patients hospitalized with COVID-19 by age group and year.

    Regarding the different age groups of children and adolescents, the mortality rates were as follows: infants aged <1 years, 1.6% (2/123); children aged 1-4 years, 4% (4/95); children aged 5-9 years, 2% (1/47); adolescents aged 10-14 years, 2% (1/40); and adolescents aged 15-19 years, 5% (4/78). There were no statistical differences between the different age groups (Fisher exact test: P=.30; Table 1 and Figure 2). Figure 3 shows the main viral infections of the patients who were COVID-19 positive in the 2 hospitals, emphasizing the importance of this disease. Table 2 shows the associated diseases of the 12 children who died from COVID-19.

    Table 1. Hospitalizations and deaths for different age groups from March 2020 to July 2023.
    Age group (years)2020202120222023Total
    Hospitalizations, nDeaths, nHospitalizations, nDeaths, nHospitalizations, nDeaths, nHospitalizations, nDeaths, nHospitalizations, nDeaths, n
    <11101817312101232
    1‐4201161422170954
    5‐99015117060471
    10‐1411116013000401
    15‐1919231026220784
    20‐291008219208247140833
    30‐3927913620761018142101499
    40‐4943127834125125111731407166
    50‐5955185981241190231931741352
    60‐695971477442872757134111650516
    70‐795001875552572989047111400545
    80‐8927314123613624794346790377
    90‐996143372282286018693
    >1004321100074
    Total28666584324116815723342243789862197
    ‎
    Figure 2. Hospitalizations and deaths of children and adolescents who were COVID-19 positive.
    ‎
    Figure 3. Percentage of hospitalized cases for COVID-19, influenza, and respiratory syncytial virus (RSV) at the hospital complex in São José do Rio Preto, according to month and etiological agent from October 1, 2021, to July 24, 2023.
    Table 2. Chief comorbidities associated with COVID-19 that led to the deaths of children and adolescents.
    Age (y)SexComorbidityInfectionAntibioticsImageVasoactive drugsMechanical ventilationIntensive care unitDialysis supportTime in hospital (mo)
    19FemaleHodgkin lymphomaYesYesCTa 25% compromised (ground-glass opacity)YesYesYesYes45
    14FemaleDown syndromeYesYesCT 70%YesYesYesYes12
    2MaleDown syndrome and heart diseaseYesYesRxbYesYesYesYes5
    19FemaleDown syndrome, schizophrenia, asthma, and corrected heart diseaseYesYesCT 50% compromisedYesYesYesYes5
    0MaleNoneYesYesRx infiltratedYesYesYesYes5
    2MaleEncephalopathyYesYesRxYesYesYesYes24
    5MaleRenal transplantYesYesCT >50% infiltrated (ground-glass opacity)YesYesYesNo20
    3MaleCongenital heart diseaseYesYesRxYesYesYesNo3
    16FemaleTumor in the central nervous systemYesYesCT >50% infiltrated (ground-glass opacity)YesYesYesYes10
    17FemaleLupusYesYesCT <25%YesYesYesNo55
    3FemaleHydranencephalyYesYesRxNoYesYesYes1
    1FemaleCongenital heart diseaseNoNoRxYesYesNoNo1

    aCT: computed tomography.

    bRx: x-ray.


    Principal Findings

    This study reports on the general mortality of children and adolescents aged <19 years and adult patients in a single university hospital complex from March 2020 to July 2023. Of the 8986 patients hospitalized with COVID-19, a total of 383 (4.26%) were children and adolescents treated at the children’s hospital. Deaths in this age group represented 0.55% (12/2197) of all deaths from COVID-19 in the institution and 3.1% (12/383) of all hospitalized patients aged <19 years. No significant difference was detected in mortality between the age groups of children and adolescents. A multicenter study in Latin America reported a mortality rate of 14% in 210 children, with 67% of those who died being treated in an intensive care unit [13].

    Observational studies in the pediatric population have shown that the presence of comorbidities is a risk factor for severe disease. Obesity, genetic disorders (such as sickle cell anemia), neurological disorders, hematological diseases, congenital heart diseases, diabetes, chronic kidney disease, asthma, and other lung diseases are pathologies that have already been associated with the severity of COVID-19 in previous studies [14]. In this study, heart disease was the main disorder reported in the children and adolescents who died.

    Regarding the age of the children and adolescents, there is no consensus on which age group has the highest or lowest severity of disease, included mortality; however, severity does seem to be linked to the presence of preexisting clinical factors. A review study reported that younger children and those with specific comorbidities, such as obesity, diabetes, heart diseases, chronic lung diseases, epilepsy, and immunocompromised conditions, are at higher risk of infection and potentially more severe consequences of COVID-19 [15,16].

    One interesting Brazilian study that analyzed a large nationwide database of hospitalized children and adolescents with laboratory-confirmed COVID-19 showed that death was associated with being aged younger than 2 years or between 12 and 19 years. Indigenous ethnicity, living in the poorest microregions, and the presence of comorbidities were also correlated with the severity of the disease. Therefore, health care disparities and social inequalities, exacerbated by interweaving comorbidities, might have contributed synergistically to magnifying the COVID-19 burden for more socioeconomically deprived and vulnerable individuals [17]. Due to uncertainties in epidemiological data on children, there is still much to learn about the manifestations of COVID-19 in this population.

    In this study, no significant differences with respect to mortality were detected between age groups of the children and adolescents; however, the number of patients is too small to arrive at any definite conclusion.

    In North America, mortality was higher in children younger than 1 year, followed by adolescents aged between 15 and 19 years [18]. In 2021 and 2022, a study in Java, Indonesia, analyzed 6441 patients aged ≤18 years who were positive for COVID-19 and reported that 2.7% of deaths occurred with other associated factors; in this study, the rate was 91.67%—a difference that may be related to the different conditions (socioeconomic factors and access to health care) in the 2 countries [19].

    Regarding mortality, since the beginning of the pandemic, newborns, children, and adolescents are less prone to this emerging condition compared to adults. Most of them experience mild symptoms; hospitalization and death of pediatric patients are rare, with deaths usually being explained by associated complications [20].

    In Ecuador, a study on mortality from 2020 to 2021 reported that out of 34,001 confirmed cases of COVID-19, a total of 258 were children and adolescents aged between 0 and 19 years and that 127 died due to COVID-19. In the same period, the study found that most deaths occurred in children aged 0 to 1 year, representing 44% (n=114) of the total deaths reported [21].

    In Brazil, in 2020, a total of 14,638 children were diagnosed with SARS, resulting in 1180 (8.06%) deaths. Being younger than 2 years was a risk factor for higher hospitalization and mortality rates [22]. In 2021, an increase in the number of cases of pediatric patients was noted; according to data from the Brazilian Ministry of Health, there were 17,644 occurrences of SARS-CoV-2 with 1263 (7.15%) deaths. This rise is related to greater knowledge of the disease, a simpler diagnosis, the larger quantity of diagnostic tests performed, and the emergence of new variants (Delta and Omicron) [9].

    Pediatric patients with comorbidities are at higher risk for hospitalization and mortality. Among the reported comorbidities, the following should be highlighted: Down syndrome, asthma, obesity, immunosuppression, and heart disease. Morbidity and mortality due to COVID-19 are not similar to other etiologies of acute respiratory distress syndrome. This is because fulminant activation of coagulation cascades can occur in COVID-19, resulting in widespread microvascular thrombosis and the consumption of clotting factors [9,22-25]. It appears that inflamed lung tissues and pulmonary endothelial cell damage may result in the formation of microthrombi that contribute to the high incidence of thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and arterial thrombotic complications.

    Another important factor that must be highlighted is the possibility of long-term symptoms such as fatigue, headaches, drowsiness, and difficulty concentrating, all of which have implications in social and educational spheres, leading to important concerns regarding the impact of the pandemic on future education levels.

    Another point to be considered is related to the risk of the long-term effects of COVID-19 on the health of the general population. Post–COVID-19 coronary changes and the presence of multisystem inflammatory syndrome were identified in some pediatric patients. Therefore, although children and adolescents represent a low percentage of COVID-19 cases in Latin America and worldwide, major social, economic, and cultural implications are linked to the disease in this population. In truth, COVID-19 has disrupted all spheres of life, including country risk factors, such as exposure to multidimensional risk drivers.

    Socioeconomic and political factors significantly influence health care conditions and directly impact the response to pandemics, including the allocation of resources for immediate health care needs. Studies analyzing the influence of demographic, economic, and political conditions in different countries and continents show a significant difference between countries with a low Human Development Index and those with a high Human Development Index. This has influenced, and continues to directly influence, human health care [26,27].

    It should be remembered that the dynamics of infections and deaths related to COVID-19 differ from country to country and are constantly changing throughout Latin America. Management requires political leadership, financial resources, and social equality, as well as the existence of informal and regional economies directed toward disadvantaged populations that traditionally have had limited access to health services. In this study, COVID-19 was the most common viral infection identified in this period. Mortality from COVID-19 in children and adolescents was lower than that in adults and was generally associated with existing diseases, with the main one being heart disease.

    This study shows results consistent with our hypothesis and with the results of studies published in MEDLINE. Thus, predicting the outcome of COVID-19 is of vital clinical importance to better allocate medical resources and provide individualized treatment for patients. The availability of clinical characteristics and parameters with potential prognostic implications will be of value for effective prevention and intervention.

    Conclusion

    Mortality from COVID-19 in children and adolescents was lower than that in adults. A second interesting finding was that these deaths were generally associated with existing diseases.

    Data Availability

    All data generated and analyzed during this study have been included within the paper.

    Authors' Contributions

    ACPdG and RBB contributed to the concept and design, acquisition of data, analysis and interpretation of data, drafting of the paper, and revising it critically for important intellectual content. ACPdG and RBB provided final approval of the version to be published.

    Conflicts of Interest

    None declared.

    1. Frenkel LD, Gomez F, Bellanti JA. COVID-19 in children: pathogenesis and current status. Allergy Asthma Proc. Jan 3, 2021;42(1):8-15. [CrossRef] [Medline]
    2. Kumar R, Aktay-Cetin Ö, Craddock V, et al. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: multilayered cross-talks in the setting of coinfections and comorbidities. PLoS Pathog. Jan 12, 2023;19(1):e1011063. [CrossRef] [Medline]
    3. Smadja DM, Mentzer SJ, Fontenay M, et al. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis. Nov 2021;24(4):755-788. [CrossRef] [Medline]
    4. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. Jun 4, 2020;135(23):2033-2040. [CrossRef] [Medline]
    5. de Siqueira Alves Lopes A, Fontes Vieira SC, Lima Santos Porto R, et al. Coronavirus disease-19 deaths among children and adolescents in an area of Northeast, Brazil: why so many? Trop Med Int Health. Jan 2021;26(1):115-119. [CrossRef] [Medline]
    6. Tsankov BK, Allaire JM, Irvine MA, et al. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J Infect Dis. Feb 2021;103:246-256. [CrossRef] [Medline]
    7. Belu A, Trandafir LM, Țarcă E, et al. Variations in biochemical values under stress in children with SARS-CoV-2 infection. Diagnostics (Basel). May 12, 2022;12(5):1213. [CrossRef] [Medline]
    8. Sayed IA, Bhalala U, Strom L, et al. Gastrointestinal manifestations in hospitalized children with acute SARS-CoV-2 infection and multisystem inflammatory condition: an analysis of the VIRUS COVID-19 Registry. Pediatr Infect Dis J. Sep 1, 2022;41(9):751-758. [CrossRef] [Medline]
    9. Sousa BLA, Silva CA, Ferraro AA. An update on the epidemiology of pediatric COVID-19 in Brazil. Rev Paul Pediatr. Apr 4, 2022;40:e2021367. [CrossRef] [Medline]
    10. Luo X, Lv M, Zhang X, et al. Clinical manifestations of COVID-19: an overview of 102 systematic reviews with evidence mapping. J Evid Based Med. Sep 2022;15(3):201-215. [CrossRef] [Medline]
    11. Souza I, Scodro R, Dias Siqueira VL, Fressatti Cardoso R, Caleffi-Ferracioli KR. Comorbidities and deaths by COVID-19 In Brazil. Revista Uningá. 2021;58:eUJ4054. URL: https://revista.uninga.br/uninga/article/view/4054 [Accessed 2025-01-29]
    12. Quast T, Andel R, Gregory S, Storch EA. Years of life lost associated with COVID-19 deaths in the USA during the first 2 years of the pandemic. J Public Health (Oxf). Aug 25, 2022;44(3):e353-e358. [CrossRef] [Medline]
    13. Dominguez-Rojas JÁ, Vásquez-Hoyos P, Pérez-Morales R, et al. Association of cancer diagnosis and therapeutic stage with mortality in pediatric patients with COVID-19, prospective multicenter cohort study from Latin America. Front Pediatr. May 3, 2022;10:885633. [CrossRef] [Medline]
    14. Pathak EB, Salemi JL, Sobers N, Menard J, Hambleton IR. COVID-19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020. J Public Health Manag Pract. 2020;26(4):325-333. [CrossRef] [Medline]
    15. Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci. Feb 7, 2022;37(5):e35. [CrossRef] [Medline]
    16. Siebach MK, Piedimonte G, Ley SH. COVID-19 in childhood: transmission, clinical presentation, complications and risk factors. Pediatr Pulmonol. Jun 2021;56(6):1342-1356. [CrossRef] [Medline]
    17. Oliveira EA, Colosimo EA, Simões E Silva AC, et al. Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database. Lancet Child Adolesc Health. Aug 2021;5(8):559-568. [CrossRef] [Medline]
    18. Flaxman S, Whittaker C, Semenova E, et al. Assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US. JAMA Netw Open. Jan 3, 2023;6(1):e2253590. [CrossRef] [Medline]
    19. Efendi F, Haryanto J, Has EMM, et al. Predictors of mortality among children with confirmed and suspected cases of COVID-19 in East Java, Indonesia. J Multidiscip Healthc. Feb 7, 2023;16:355-362. [CrossRef] [Medline]
    20. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. Sep 1, 2020;174(9):882-889. [CrossRef] [Medline]
    21. Ortiz-Prado E, Izquierdo-Condoy JS, Fernandez-Naranjo R, et al. The deadly impact of COVID-19 among children from Latin America: the case of Ecuador. Front Pediatr. Apr 21, 2023;11:1060311. [CrossRef] [Medline]
    22. Ministério da Saúde (Brazil). SRAG 2020 - banco de dados de síndrome respiratória aguda grave - incluindo dados da COVID-19. Open Data SUS. 2020. URL: https://opendatasus.saude.gov.br/dataset/srag-2020 [Accessed 2021-10-19]
    23. Mucalo L, Brandow AM, Dasgupta M, et al. Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Blood Adv. Jul 13, 2021;5(13):2717-2724. [CrossRef] [Medline]
    24. Trapani S, Rubino C, Lasagni D, et al. Thromboembolic complications in children with COVID-19 and MIS-C: a narrative review. Front Pediatr. Aug 11, 2022;10:944743. [CrossRef] [Medline]
    25. Conway EM, Mackman N, Warren RQ, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. Oct 2022;22(10):639-649. [CrossRef] [Medline]
    26. Renzaho AMN. The need for the right socio-economic and cultural fit in the COVID-19 response in sub-Saharan Africa: examining demographic, economic political, health, and socio-cultural differentials in COVID-19 morbidity and mortality. Int J Environ Res Public Health. May 15, 2020;17(10):3445. [CrossRef] [Medline]
    27. Heo MH, Kwon YD, Cheon J, Kim KB, Noh JW. Association between the Human Development Index and confirmed COVID-19 cases by country. Healthcare (Basel). Jul 29, 2022;10(8):1417. [CrossRef] [Medline]

    Edited by Sherif Badawy; submitted 14.10.24; peer-reviewed by Mikhail M Kostik, Seung Won Lee; final revised version received 14.01.25; accepted 15.01.25; published 20.05.25.

    Copyright

    © Ana Carolina Pereira de Godoy, Reinaldo Bulgarelli Bestetti. Originally published in JMIR Pediatrics and Parenting (https://pediatrics.jmir.org), 20.5.2025.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Pediatrics and Parenting, is properly cited. The complete bibliographic information, a link to the original publication on https://pediatrics.jmir.org, as well as this copyright and license information must be included.